Nilotinib Teva Uk Limited (Nilotinib Hydrochloride Dihydrate)

Nilotinib works by binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that leads to uncontrolled proliferation of leukemic cells. The drug also inhibits other kinases such as KIT and PDGFR, adding to its antineoplastic effect.

The dose of nilotinib is determined by the prescribing physician based on the patient’s disease phase, overall health, liver function, and potential drug interactions. Dosage adjustments may be required for patients with hepatic impairment or those taking concomitant medications that affect nilotinib metabolism.

Nilotinib is classified as pregnancy category unknown and is generally not recommended for use during pregnancy or lactation. Women of childbearing potential should use effective contraception during treatment and for a defined period after discontinuation, and breastfeeding should be avoided.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to nilotinib is imatinib, another BCR‑ABL inhibitor. Nilotinib is more potent against certain BCR‑ABL mutations and often achieves faster and deeper molecular responses, but it may have a higher incidence of cardiovascular and metabolic side effects. Choice of therapy depends on mutation profile, patient comorbidities and physician judgment.

Nilotinib tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack. They must be kept away from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Nilotinib is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). The tablets should be swallowed whole with a glass of water and not crushed or chewed. Patients must follow the dosing schedule prescribed by their healthcare provider.

Serious risks include cardiovascular events such as arterial occlusion or myocardial infarction, hepatotoxicity manifested by elevated liver enzymes or hepatitis, and pancreatitis. Patients should be monitored regularly for signs of chest pain, liver dysfunction, abdominal pain, or unexplained nausea and report any concerning symptoms promptly.

Nilotinib should be avoided in patients with a known hypersensitivity to the drug or any of its excipients, in those with uncontrolled cardiovascular disease, and in pregnant or breastfeeding women. Caution is also advised for individuals with severe hepatic impairment or those taking strong CYP3A4 inhibitors.